Antidiabetic agents in subjects with mild dysglycaemia: prevention or early treatment of type 2 diabetes?

Diabetes and Metabolism

Volumn 33, Issue 1, 2007, Pages 3-12

  Scheen, A J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Acarbose; Glinide; Glitazone; Impaired fasting glucose; Impaired glucose tolerance; Metformin; Prediabetes; Prevention; Review; Sulphonylurea; Thiazolidinedione; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; INSULIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; ROSIGLITAZONE; TOLBUTAMIDE; TROGLITAZONE; VALSARTAN; SULFONYLUREA DERIVATIVE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG DOSE TITRATION; DYSGLYCAEMIA; HUMAN; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK FACTOR; SIDE EFFECT; WEIGHT REDUCTION; HYPERGLYCEMIA;

ACARBOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 34247248252     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2006.11.005     Document Type: Review

References (88)

1. Harris M.I. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 23 (2000) 754-758
2. Massi-Benedetti M., and CODE-2 Advisory Board. The cost of diabetes type II in Europe. The CODE-2 study. Diabetologia 45 7 (2002) S1-S4
3. Scheen A.J., and Lefèbvre P.J. Insulin resistance versus insulin deficiency: which one comes first? The old question revisited. In: Di Mario U., Leonetti F., Pugliese G., Sbraccia P., and Signore A. (Eds). Diabetes in the New Millennium (2000), Wiley & Sons, New York 101-113
4. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46 (2003) 3-19
5. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365 (2005) 1333-1346
6. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
7. Scheen A.J. Obesity and diabetes. In: Kopelman P.G. (Ed). The management of obesity and related disorders (2001), Martin Dunitz Ltd, London, UK 11-44
8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. -Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care 26 (2003) 3160-3167
10. Edelstein S.L., Knowler W.C., Bain R.P., Andres R., Barrett-Connor E.L., Dowse G.K., et al. Predictors of progression from impaired glucose tolerance to NIDDM. An analysis of six prospective studies. Diabetes 46 (1997) 701-710
11. Harris R., Donahue K., Rathore S.S., Frame P., Woolf S.H., and Lohr K.N. Screening adults for type 2 diabetes: a review of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 138 (2003) 215-229
12. WHO Study Group. Prevention of diabetes mellitus: report of WHO study group. WHO Tech. Rep. Ser. 844 (1994) 1-100
13. In: Donelly R., and Garber A. (Eds). Progression of type 2 diabetes-inevitable or preventable?. Diab Obes Metab 3 Suppl. 1 (2001) S1-S43
14. American Diabetes Association and National Institute of Diabetes. Digestive and Kidney Diseases. The prevention or delay of type 2 diabetes. Diabetes Care 25 (2002) 742-749
15. Tuomilehto J., Lindström J., Ericksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344 (2001) 1343-1350
16. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
17. Zimmet P., Shaw J., and Alberti K.G.M.M. Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet. Med. 20 (2003) 693-702
18. Davies M.J., Tringham J.R., Troughton J., and Khunti K.K. Prevention of Type 2 diabetes mellitus: a review of the evidence and its application in a UK setting. Diabet. Med. 21 (2004) 403-414
19. Schulze M.B., and Hu F.B. Primary prevention of diabetes: what can be done and how much can be prevented?. Annu. Rev. Public Health 26 (2005) 445-467
20. Chiasson J.L., and Rabasa-Lhoret R. Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes 53 Suppl. 3 (2004) S34-S38
21. Simpson R.W., Shaw J.E., and Zimmet P.Z. The prevention of type 2 diabetes-lifestyle change or pharmacotherapy?. Diabetes Res. Clin. Pract. 103 (2003) 357-362
22. Liberopoulos E.N., Tsouli S., Mikhailidis D.P., and Elisaf M.S. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr. Drug Targets 7 (2006) 211-228
23. Scheen A.J. Pharmacological prevention of type 2 diabetes. In: Ekoe J.M., Zimmet P., Williams R., and Rewers M. (Eds). The epidemiology of diabetes mellitus. An international perspective (2007), John Wiley & Sons, London, UK [in press]
24. Freemark M. Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. J. Clin. Endocrinol. Metab. 88 (2003) 3-13
25. Krentz A.J., and Bailey C.J. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65 (2005) 385-411
26. Padwal R., Majumdar S.R., Johnson J.A., Varney J., and McAlister F.A. A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care 28 (2005) 736-744
27. Anderson Jr. D.C. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann. Pharmacother. 39 (2005) 102-109
28. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomized clinical trials. Diabetes Metab. 30 (2004) 487-496
29. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 30 (2004) 498-505
30. Buchanan T.A. Prevention of type 2 diabetes. What is it really?. Diabetes Care 26 (2003) 1306-1308
31. Scheen A.J. Preventing, delaying or masking type 2 diabetes with metformin in the Diabetes Prevention Program?. Diabetes Care 26 (2003) 2701
32. Consoli A., Gomis R., Halimi S., Home P.D., Mehnert H., Strojek K., et al. Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab. 30 (2004) 509-516
33. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29 (2006) 1963-1972 [and Diabetologia 2006;49:1711-21]
34. Cusi K., and DeFronzo R.A. Metformin: a review of its metabolic effects. Diabetes Rev 6 (1998) 89-131
35. Fontbonne A., Charles M.A., Juhan-Vague I., and BIGPRO Study Group. The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. Diabetes Care 19 (1994) 920-926
36. Tiikkainen M., Häkkinen A.M., Korsheninnikova E., Nyman T., Makimattila S., and Yki-Jarvinen H. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53 (2004) 2169-2176
37. Scheen A.J., Letiexhe M.R., and Lefèbvre P.J. Short administration of metformin improves insulin sensitivity in obese android subjects with impaired glucose tolerance. Diabet. Med. 12 (1995) 985-989
38. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 26 (2003) 977-980
39. Yang W., Lin L., and Qi J. The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentre prospective study. Chin J. Endocrinol. Metab. 17 (2001) 131-136
40. Holman R.R., Blackwell L., Stratton I.M., Manley S.E., Tucker L., and Frighi V. Six-year results from the Early Diabetes Intervention Trial. Diabet. Med. 20 Suppl. 2 (2003) S15 (Abstract)
41. Ramachandran A., Snehalatha C., Mary S., Mukesh B., Bhaskar A.D., Vijay V., et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49 (2006) 289-297
42. Scheen A.J. Pathophysiology of insulin secretion. Ann. Endocrinol. (Paris) 65 (2004) 29-36
43. Ferrannini E., Gastaldelli A., Miyazaki Y., Matsuda M., Mari A., and DeFronzo R.A. β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J. Clin. Endocrinol. Metab. 90 (2005) 493-500
44. Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64 (2004) 1339-1358
45. Alberti K.G.M.M. The clinical implications of impaired glucose tolerance. Diabet. Med. 13 (1996) 927-937
46. Keen H., Jarrett R.J., Ward J.D., and Fuller J.H. Boderline diabetics and their response to tolbutamide. Adv. Metab. Disord. 2 Suppl. 2 (1973) 521-531
47. Sartor G., Schersten B., Carlstrom S., Melander A., Norden A., and Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 29 (1980) 41-49
48. Herlihy O.M., Morris R.J., Karunakaran S., and Holman R. Sulphonylurea therapy over six years does not delay progression to diabetes. Diabetologia 43 Suppl. 1 (2000) A73 (Abstract)
49. Lindblad U., Lindwall K., Sjostrand A., Ranstam J., and Melander A. The NEPI Antidiabetes Study (NANSY). 1. Short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes Obes. Metab. 3 (2001) 443-451
50. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 358 (2001) 1709-1716
51. The NAVIGATOR Trial Steering Committee. Nateglinide and valsartan in impaired glucose tolerance outcomes research, rationale and design of the NAVIGATOR trial. Diabetes 51 Suppl. 2 (2002) A116 (Abstract)
52. Yki-Järvinen H. Thiazolidinediones. N. Engl. J. Med. 351 (2004) 1106-1118
53. Leiter L.A. Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes. Diabet. Med. 22 (2005) 963-972
54. Walter H., and Lubben G. Potential role of oral thiazolidinedione therapy in preservation of beta-cell function in type 2 diabetes mellitus. Drugs 65 (2005) 1-13
55. Buchanan T.A., Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51 (2002) 2796-2803
56. Scheen A.J. Hepatotoxicity with thiazolidinediones. Is it a class effect?. Drug Saf. 24 (2001) 873-888
57. Xiang A.H., Peters R.K., Kjos S.L., Marroquin A., Goico J., Ochoa C., et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55 (2006) 517-522
58. Durbin R.J. Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes. Metab. 6 (2004) 280-285
59. The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54 (2005) 1150-1156
60. The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368 (2006) 1096-1105
61. Tuomiletho J., and Wareham N. Glucose lowering and diabetes prevention: are they the same?. Lancet 368 (2006) 1218-1219
62. HOPE/HOPE-TOO Study Investigators. Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE study extension. Circulation 112 (2005) 1339-1346
63. ACT-NOW. http://www.uthscsa.edu/hscnews/singleformat.asp?newID=845&SearchID=.
64. Lebovitz H.E. α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev. 6 (1998) 132-145
65. Scheen A.J. Is there a role to α-glucosidase inhibitors in the prevention of type 2 diabetes?. Drugs 63 (2003) 933-951
66. Chiasson J.-L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., et al., STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359 (2002) 2072-2077
67. Scheen A.J. Acarbose for type 2 diabetes prevention. Lancet 360 (2002) 1516 (Letter)
68. Kaiser T., and Sawicki P.T. For debate. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia 47 (2004) 575-580
69. Chiasson J.-L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., et al. Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM trial data. Diabetologia 47 (2004) 969-975
70. Van de Laar F.A., Lucassen P.L., Akkermans R.P., Van de Lisdonk E.H., and De Grauw W.J. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database Syst. Rev. (2006) Issue 4. Art. No: CD005061 DOI:10.1002/14651858.CD005061.pub2.
71. Gerstein H.C., and Rosenstock J. Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation?. Endocrinol. Metab. Clin. North Am. 34 (2005) 137-154
72. Scheen A.J. Clinical pharmacokinetics of metformin. Clin Pharmacokin 30 (1996) 359-371
73. Scheen A.J., Letiexhe M.R., and Lefèbvre P.J. Effects of metformin in obese patients with impaired glucose tolerance. Diabetes Metab. Rev. 11 (1995) S69-S80
74. Herman W.H., Hoerger T.J., Brandle M., Hicks K., Sorensen S., Zhang P., et al., Diabetes Prevention Program Research Group. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann. Intern. Med. 142 (2005) 323-332
75. Walker E.A., Molitch M., Kramer M.K., Kahn S., Ma Y., Edelstein S., et al., Diabetes Prevention Program Research Group. Adherence to prevention medications. Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 29 (2006) 1997-2002
76. Eddy D.M., Schlessinger L., and Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann. Intern. Med. 143 (2005) 251-264
77. Freemark M., and Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 107 (2001) 1-7
78. Zinman B., Harris S.B., Gerstein H.C., Young T.K., Raboud J.M., Neuman J., et al. Preventing type 2 diabetes using combination therapy: design and methods of the Canadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes Obes. Metab. 8 (2006) 531-537
79. Baggio L.L., and Drucker D.J. Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu. Rev. Med. 57 (2006) 265-281
80. Gautier J.F., Fetita S., Sobngwi E., and Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 31 (2005) 233-242
81. Holst J.J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture 2005. Diabetologia 49 (2006) 253-260
82. Josse R.G., McGuire A.J., and Saal G.B. A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. Int. J. Clin. Pract. 60 (2006) 847-855
83. Karasik A. Glycaemic control is essential for effective cardiovascular risk reduction across the type 2 diabetes continuum. Ann. Med. 37 (2005) 250-258
84. Petersen J.L., and McGuire D.K. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diab. Vasc. Dis. Res. 2 (2005) 9-15
85. Matsuda M., Mari A., and DeFronzo R. World Health Organization & International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation (2006), WHO Press, Geneva 1-46
86. Heneghan C., Thompson M., and Perera R. Prevention of diabetes. Drugs trials show promising results, but have limitations. BMJ 333 (2006) 764-765
87. Lindstrom J., Ilanne-Parikka P., Peltonen M., Aunola S., Eriksson J.G., Hemio K., et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368 (2006) 1673-1679
88. Libman I.M., and Arslanian S.A. Prevention and treatment of type 2 diabetes in youth. Horm. Res. 28 (2006) 22-34